644 related articles for article (PubMed ID: 27329952)
1. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
[TBL] [Abstract][Full Text] [Related]
2. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
3. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
4. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
6. CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia.
Mello E Silva A; Aguiar C; Sequeira Duarte J; Couto L; Teixeira Veríssimo M; Marques da Silva P
Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):531-542. PubMed ID: 31447268
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
9. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
10. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
Jacobson TA; Ito MK; Maki KC; Orringer CE; Bays HE; Jones PH; McKenney JM; Grundy SM; Gill EA; Wild RA; Wilson DP; Brown WV
J Clin Lipidol; 2015; 9(2):129-69. PubMed ID: 25911072
[TBL] [Abstract][Full Text] [Related]
11. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
[TBL] [Abstract][Full Text] [Related]
12. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
13. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
14. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
[TBL] [Abstract][Full Text] [Related]
15. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
17. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
18. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
19. The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes.
Stahel P; Xiao C; Hegele RA; Lewis GF
Can J Cardiol; 2018 May; 34(5):595-604. PubMed ID: 29459241
[TBL] [Abstract][Full Text] [Related]
20. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?
Rizzo M; Berneis K
J Atheroscler Thromb; 2005; 12(5):237-9. PubMed ID: 16205019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
